 The purpose of this study is to evaluate whether a therapy with an all once daily regimen of stavudine extended release d4T XR, lamivudine 3TC, and efavirenz EFV leads to improved outcomes, as measured by viral load, CD4 counts, adherence, safety, and tolerability. 